Showing 1381-1390 of 1616 results for "".
- Aurion Biotech Names Members of Medical Advisory Boardhttps://modernod.com/news/aurion-biotech-names-members-of-medical-advisory-board/2480358/Aurion Biotech announced the company’s medical advisory board, composed of the world’s most eminent ophthalmologists. The board will collaborate with the company’s executive team in clinical development, and is chaired by Edward Holland, MD, who was recently
- Gemini Therapeutics Announces Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021https://modernod.com/news/gemini-therapeutics-announces-data-from-its-ongoing-phase-2a-study-of-gem103-at-euretina-2021/2479579/Gemini Therapeutics announced that Raj Maturi, MD, Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, presented Gemini’s previously released initial results from its ongoing phase 2a study at EURETINA 2021
- Eye Health America Acquires Two Florida Eye Practiceshttps://modernod.com/news/eye-health-america-acquires-two-florida-eye-practices/2479473/Eye Health America (EHA) has acquisition Nielsen Eye Center and Eye Centers of Florida. Nielsen Eye Center is joining Updegraff Laser Vision to expand Eye Health America’s continuum of patient care in the Tampa Bay area. James Nielsen, MD established his practice in Pinellas County
- Oyster Point Pharma Names Donald Santel as Chairman of the Board of Directorshttps://modernod.com/news/oyster-point-pharma-names-donald-santel-as-chairman-of-the-board-of-directors/2479427/Oyster Point Pharma announced the appointment of Donald Santel as non-executive Chairperson and a Director of the company and a member of the Compensation Committee. Mr. Santel joined the Board on July 30, 2021, and will take over as Chairperson as Ali Behbahani, MD, steps down as Ch
- Holland Foundation for Sight Restoration Launched to Provide Life Changing Eye Surgerieshttps://modernod.com/news/holland-foundation-for-sight-restoration-launched-to-provide-life-changing-eye-surgeries/2479402/Edward Holland, MD, a pioneering ophthalmologist in the treatment of Severe Ocular Surface Disease, today announced the launch of the Holland Foundation for Site Restoration with a goal of establishing Centers of Excellence (COEs) throughout the country that would specialize in site restoration p
- Ocuphire to Present at Multiple Ophthalmic Conferences in Julyhttps://modernod.com/news/ocuphire-to-present-at-multiple-ophthalmic-conferences-in-july/2479363/Ocuphire Pharma announced that Jay S. Pepose, MD, Medical Advisor and Board Director, will be presenting two papers on presbyopia and reversal of mydriasis (RM) at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting on July 23-27, 2021 and that Mina Sooch, CEO and
- Allergan Adds Two Experts to Eye Care Divisionhttps://modernod.com/news/allergan-adds-two-experts-to-eye-care-division/2479311/Allergan has announced two new additions to leadership roles in Allergan Eye Care. E. Randy Craven, MD, FACS, has joined Allergan Eye Care as medical director of the U.S. medical affairs glaucoma organization. A pioneer of minimally-invasive glaucoma surgery, Dr. Craven previously served a
- Iveric Bio to Present Zimura GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyseshttps://modernod.com/news/iveric-bio-to-present-zimura-gather2-enrollment-and-retention-updates-and-new-gather1-post-hoc-analyses/2479306/Iveric bio announced that today at the company’s Virtual Symposium for Investors and Analysts, Arshad M. Khanani, MD, MA, of Sierra Eye Associates, and Chairman of the GATHER2 Steering Committee, will discuss an accelerated enrollment timeline and patient retention, including injection fidelity,
- Oxular Appoints Dr. Friedrich Asmus as Chief Medical Officerhttps://modernod.com/news/oxular-appoints-dr-friedrich-asmus-as-chief-medical-officer/2479267/Oxular Limited announced it has appointed Friedrich (Fritz) Asmus, MD, as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to further the company’s lead asset, OXU‑001, for the treatment of diabetic macular edema (DME), and to accelerate the development o
- Oxurion Appoints Tom Graney, CFA, as Chief Executive Officerhttps://modernod.com/news/oxurion-appoints-tom-graney-cfa-as-chief-executive-officer/2479215/Oxurion NV announced in a planned succession, the promotion of Tom Graney, CFA, from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Patrik De Haes, MD, who after 14 years as CEO has decided to move away from day-to-day management